会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 12. 发明公开
    • HIV NC 단백질 발현용 벡터 및 이를 이용한 NC단백질의 생산방법
    • 用于表达HIV蛋白质的载体和使用其生产NC蛋白的方法
    • KR1020080057750A
    • 2008-06-25
    • KR1020060131392
    • 2006-12-20
    • 유지창(주) 에빅스젠
    • 유지창
    • C12N15/64C12N15/09
    • An HIV NC(nucleocapsid) protein expression vector is provided to express a wild type NC protein in an animal cell and improve the expression efficiency of the NC protein compared with conventional techniques. An HIV NC protein expression vector is characterized in that at least one sequence selected from the group consisting of an SV40 19s mRNA intron sequence, a mutated SV40 16S mRNA intron sequence and a beta-globin intron sequence, an HIV NC gene, and an mRNA stability element selected from the group consisting of RRE(Rev response element), WPRE(woodchuck posttranscriptional regulatory element), beta-actin 3'-untranslated regions and RSV(Rous Sarcoma Virus) stability element are linked in sequence. A method for producing the HIV NC protein comprises a step of culturing a cell transformed by the vector, wherein the cell is COS-7 or 293T cell.
    • 提供HIV NC(核衣壳)蛋白表达载体,以在动物细胞中表达野生型NC蛋白,并提高NC蛋白与常规技术相比的表达效率。 HIV NC蛋白表达载体的特征在于,选自SV4019s mRNA内含子序列,突变SV40 16S mRNA内含子序列和β-珠蛋白内含子序列,HIV NC基因和mRNA中的至少一种序列 选自RRE(Rev响应元件),WPRE(土拨鼠转录调控元件),β-肌动蛋白3'-非翻译区和RSV(Rous肉瘤病毒)稳定性元件的稳定性元件依次连接。 制备HIV NC蛋白质的方法包括培养由载体转化的细胞的步骤,其中细胞是COS-7或293T细胞。
    • 13. 发明公开
    • 외부 유전자가 형질도입된 염색체를 포함하는 사람의 면역결핍바이러스 억제제의 탐색을 위한 형질전환체
    • 改造高效筛选艾滋病毒抑制剂,将含有外源DNA和一种NC蛋白表达载体的染色体
    • KR1020050022417A
    • 2005-03-08
    • KR1020030060613
    • 2003-08-30
    • 유지창
    • 유지창
    • C12N15/70
    • C12N15/70C07K14/47C12Q1/025C12Q1/34
    • PURPOSE: A transformant for screening a HIV inhibitor harboring the chromosome integrated with foreign DNA is provided, thereby improving efficiency of HIV(human immunodeficiency virus) inhibitor screening method by using only one expression vector expressing a NC protein in comparison with the prior methods using two expression vectors. CONSTITUTION: The transformant for screening a HIV inhibitor harbors the chromosome containing a nucleotide sequence which can be transcribed into a psi RNA nucleotide sequence, and gene lacZ, sequentially, and an expression vector expressing NC protein. The method for screening the HIV inhibitor comprises the steps of: (i) culturing the transformant for screening the HIV inhibitor; (ii) treating the cultured transformant with a compound which is suspected as a HIV inhibitor; and (iii) measuring the expression level of beta-galactosidase from the compound treated transformant.
    • 目的:提供一种用于筛选携带与外来DNA整合的染色体的HIV抑制剂的转化体,从而通过仅使用一种表达NC蛋白的表达载体与现有方法相比较,使用两种方法,提高了HIV(人类免疫缺陷病毒)抑制剂筛选方法的效率 表达载体。 构成:用于筛选HIV抑制剂的转化体含有含有可以转录成psi RNA核苷酸序列和基因lacZ,以及表达NC蛋白的表达载体的核苷酸序列的染色体。 筛选HIV抑制剂的方法包括以下步骤:(i)培养用于筛选HIV抑制剂的转化体; (ii)用疑似为HIV抑制剂的化合物处理培养的转化体; 和(iii)从化合物处理的转化体测量β-半乳糖苷酶的表达水平。
    • 14. 发明授权
    • 제 1형 인간면역결핍 바이러스의 뉴클레오 캡시드 단백질에 결합하는 RNA
    • 제1인간간역결핍바이러스의뉴클레오캡시드단백질에결합하RNA RNA
    • KR100435634B1
    • 2004-06-12
    • KR1020010052594
    • 2001-08-29
    • (주) 에빅스젠정선주유지창
    • 유지창정선주남혁준김세진
    • C12N15/48
    • PURPOSE: RNAs capable of binding with a nucleocapsid protein of HIV-1(human immunodeficiency virus-1) are provided, thereby inhibiting the function of nucleocapsid protein and the growth of HIV-1. Therefore, the RNAs can be useful for prevention and treatment of HIV. CONSTITUTION: The RNAs capable of binding with the nucleocapsid protein of HIV-1 include RNA #SE8-4 having the nucleotide sequence of SEQ ID NO: 1, RNA #SE10-3 having the nucleotide sequence of SEQ ID NO: 2, RNA #SE10-12 having the nucleotide sequence of SEQ ID NO: 3, RNA #SE10-7 having the nucleotide sequence of SEQ ID NO: 4, RNA #SE8-6 having the nucleotide sequence of SEQ ID NO: 5, RNA #SE10-1 having the nucleotide sequence of SEQ ID NO: 6, RNA #SE10-8 having the nucleotide sequence of SEQ ID NO: 7, RNA #SE8-11 having the nucleotide sequence of SEQ ID NO: 8, RNA #SE8-10 having the nucleotide sequence of SEQ ID NO: 9, RNA #SE10-2 having the nucleotide sequence of SEQ ID NO: 10, RNA #SE10-11 having the nucleotide sequence of SEQ ID NO: 11, RNA #SE8-7 having the nucleotide sequence of SEQ ID NO: 12, RNA #SE8-13 having the nucleotide sequence of SEQ ID NO: 13, RNA #SE10-9 having the nucleotide sequence of SEQ ID NO: 14 and RNA #SE10-4 having the nucleotide sequence of SEQ ID NO: 15.
    • 目的:提供能够与HIV-1(人类免疫缺陷病毒-1)的核衣壳蛋白结合的RNA,从而抑制核衣壳蛋白的功能和HIV-1的生长。 因此,RNA可用于预防和治疗HIV。 构成:能够与HIV-1的核衣壳蛋白结合的RNA包括具有SEQ ID NO:1的核苷酸序列的RNA#SE8-4,具有SEQ ID NO:2的核苷酸序列的RNA#SE10-3,具有SEQ ID NO: 具有SEQ ID NO:3的核苷酸序列的SE10-12,具有SEQ ID NO:4的核苷酸序列的RNA#SE10-7,具有SEQ ID NO:5的核苷酸序列的RNA#SE8-6,具有SEQ ID NO: 1具有核苷酸序列SEQ ID NO:6,具有SEQ ID NO:7核苷酸序列的RNA#SE10-8,具有SEQ ID NO:8核苷酸序列的RNA#SE8-11,具有SEQ ID NO: SEQ ID NO:9的核苷酸序列,具有SEQ ID NO:10的核苷酸序列的RNA#SE10-2,具有SEQ ID NO:11的核苷酸序列的RNA#SE10-11,具有该核苷酸的RNA#SE8-7 SEQ ID NO:12的序列,具有SEQ ID NO:13的核苷酸序列的RNA#SE8-13,具有SEQ ID NO:14的核苷酸序列的RNA#SE10-9和具有 SEQ ID NO:15。
    • 15. 发明公开
    • 역전사 중합효소 연쇄반응을 이용한 마이코박테리움레프레의 약제 감수성 측정방법
    • 使用反向转录 - 聚合酶链反应(RT-PCR)的MYCOBACTERIUM LEPRAE的药物敏感性测试方法
    • KR1020010094219A
    • 2001-10-31
    • KR1020000017727
    • 2000-04-04
    • 유지창
    • 유지창김민주김세곤김상헌
    • C12Q1/00
    • PURPOSE: Provided is a drug sensitivity test method for Mycobacterium leprae(hereafter referred to as M.leprae), using reverse transcription polymerase chain reaction(RT-PCR), thereby assaying drug efficacy in a simple, fast, reliable, accurate and sensible manner compared with other existing tests which need costly equipment. The method can be used in developing therapeutic agents in Hansen's disease and deciding the effectiveness of chemotherapeutic treatment in Hansen's disease. CONSTITUTION: The test method comprises steps of: (i) infecting M.leprae to a host cell in a ratio of cell number to M.leprae number being 1:10 to 1:30, for 8 hours, where the host cell is characteristically mouse macrophage cell line IC-21, J77rA.l, RAW 264.17 or THP-1 and treating an antibiotics for Hansen's disease for 12 to 24 hours to test sensitivity, where antibiotics is selected from rifampin, Dapsone(4,4-diamino diphenyl sulfone), clofazimine, mimocin, ethonamide, fluoroquinolones, macrolide antibiotics, minocycline and fusidic acid; (ii) separating M.leprae from the host cell, extracting RNA from separated M.leprea and obtaining cDNA by reverse transcription from the extracted RNA as a template; (iii) amplifying the obtained cDNA by polymerase chain reaction(PCR) using M.leprae-specific 18kDa gene primer 1(SEQ NO ID:1) and 2(SEQ ID NO:2) and the reaction target base sequence selected from the group consisting of the heat shock protein, hsp 10, 14, 34, 45, 65 or 70 gene, Dmak gene, GroEl gene, 16S rRNA, 16S rRNA, M.leprae-specific 18kDa gene, and M.leprae specific repetitive sequence and finally performing agarose gel electrophoresis.
    • 目的:提供使用逆转录聚合酶链反应(RT-PCR)的麻风分枝杆菌药物敏感性试验方法(以下简称M.leprae),从而以简单,快速,可靠,准确,合理的方式测定药物疗效 与其他需要昂贵设备的现有测试相比。 该方法可用于开发汉森氏病的治疗药物,并确定汉森氏病中化学治疗的有效性。 构成:测试方法包括以下步骤:(i)将宿主细胞以细胞数与M.leprae数的比例感染M.leprae为1:10至1:30,持续8小时,其中宿主细胞特征性 小鼠巨噬细胞细胞系IC-21,J77rA.l,RAW 264.17或THP-1,并将抗生素用于汉森氏病12-24小时,以检测敏感性,其中抗生素选自利福平,氨苯砜(4,4-二氨基二苯砜 ),clofazimine,mimocin,乙酰胺,氟喹诺酮类,大环内酯类抗生素,米诺环素和夫西地酸; (ii)从宿主细胞中分离出M.leprae,从分离的M.leprea提取RNA,通过逆转录从提取的RNA作为模板获得cDNA; (iii)使用M.leprae特异性18kDa基因引物1(SEQ ID NO:1)和2(SEQ ID NO:2)通过聚合酶链反应(PCR)扩增获得的cDNA,并且选自下组的反应靶基序列 由热休克蛋白,hsp 10,14,44,45,65或70基因,Dmak基因,GroE1基因,16S rRNA,16S rRNA,M.leprae特异性18kDa基因和M.leprae特异性重复序列组成,最后 进行琼脂糖凝胶电泳。
    • 17. 发明公开
    • AIDS 예방 및 치료 물질 스크리닝용 재조합 포유동물세포 및 이를 이용한 스크리닝 방법
    • 用于筛选防止和治疗艾滋病的物质的重组妈妈细胞和使用其的筛选方法
    • KR1020080079592A
    • 2008-09-01
    • KR1020080013918
    • 2008-02-15
    • 유지창(주) 에빅스젠
    • 유지창
    • C12N15/06C12N15/09C12N15/10C12N15/48
    • G01N33/5008G01N2800/24
    • A recombinant mammalian cell is provided to screen a substance capable of preventing and treating AIDS(acquired immune deficiency syndrome) by inhibiting interaction between HIV(human immunodeficiency virus) NC(nucleocapsid) protein and HIV Psi(psi) sequence associated with HIV packaging. A recombinant mammalian cell for screening a substance capable of preventing and treating AIDS is produced by being transformed into (a) an HIV NC expression cassette having a promoter and a polynucleotide encoding a polypeptide containing HIV NC protein having the amino acid sequence of SEQ ID NO:1 operatively linked thereto, and (b) a reporter gene expression cassette containing a promoter, HIV Psi sequence having the nucleotide sequence of SEQ ID NO:2 operatively linked thereto and a reporter gene selected from EGFP(enhanced green fluorescent protein), GFP(green fluorescent protein), luciferase, gaussia luciferase, beta-galactosidase and alkaline phosphatase. A screening method of a substance capable of preventing and treating AIDS comprises the steps of: (a) treating a recombinant mammalian cell with a candidate substance; and (b) measuring the expression level of a reporter gene in the cultured cell.
    • 提供重组哺乳动物细胞以通过抑制HIV(人免疫缺陷病毒)NC(核衣壳)蛋白与HIV包装相关的HIV Psi(psi)序列之间的相互作用来筛选能够预防和治疗AIDS(获得性免疫缺陷综合征)的物质)。 用于筛选能够预防和治疗AIDS的物质的重组哺乳动物细胞通过转化成(a)具有启动子和编码含有具有SEQ ID NO的氨基酸序列的HIV NC蛋白的多肽的多核苷酸的HIV NC表达盒来产生 :1可操作地连接到其上,和(b)含有启动子的报告基因表达盒,具有与其可操作地连接的SEQ ID NO:2的核苷酸序列的HIV Psi序列和选自EGFP(增强的绿色荧光蛋白),GFP (绿色荧光蛋白),萤光素酶,高丝萤光素酶,β-半乳糖苷酶和碱性磷酸酶。 能够预防和治疗AIDS的物质的筛选方法包括以下步骤:(a)用候选物质处理重组哺乳动物细胞; 和(b)测量培养细胞中报告基因的表达水平。